22.17
-0.63(-2.76%)
Currency In USD
| Previous Close | 22.8 |
| Open | 22.75 |
| Day High | 23.89 |
| Day Low | 22 |
| 52-Week High | 41.3 |
| 52-Week Low | 3.6 |
| Volume | 222,450 |
| Average Volume | 204,075 |
| Market Cap | 154.21M |
| PE | -1.43 |
| EPS | -15.54 |
| Moving Average 50 Days | 13.46 |
| Moving Average 200 Days | 11.69 |
| Change | -0.63 |
If you invested $1000 in Scilex Holding Company (SCLX) since IPO date, it would be worth $64.31 as of September 09, 2025 at a share price of $22.17. Whereas If you bought $1000 worth of Scilex Holding Company (SCLX) shares 3 years ago, it would be worth $61.22 as of September 09, 2025 at a share price of $22.17.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. Announce Approval from Denali’s Shareholders of the Previously Announced Business Combination
GlobeNewswire Inc.
Sep 04, 2025 1:00 PM GMT
PALO ALTO, Calif, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Semnur Pharmaceuticals, Inc. (“Semnur”), a majority-owned subsidiary of Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acqu
Scilex Holding Company (Nasdaq: SCLX) Announces Its Majority-Owned Subsidiary, Semnur Pharmaceuticals, Inc. (“Semnur”), and Denali Capital Acquisition Corp. Have Entered into a Purchase Agreement with an Investor for a $20 Million Private Placement at $16.00 per share and Jaisim Shah, Scilex’s CEO and President, Will be Dedicated to Semnur on a Full Time Basis to Rapidly Advance SP-102 to Regulatory Approval and Commercialization for the Treatment of Lumbosacral Radicular Pain (LRP)/Sciatica
GlobeNewswire Inc.
Aug 21, 2025 10:00 AM GMT
PALO ALTO, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management product
Scilex Holding Company (Nasdaq: SCLX) Announces Effectiveness of Registration Statement on Form S-4 for the Proposed Business Combination of Denali Capital Acquisition Corp. and Semnur Pharmaceuticals, Inc., a Majority-Owned Subsidiary of Scilex
GlobeNewswire Inc.
Aug 13, 2025 10:00 AM GMT
Denali’s registration statement on Form S-4 declared effective by the Securities and Exchange CommissionExtraordinary general meeting of Denali Capital Acquisition Corp. shareholders to approve the proposed business combination is scheduled to be hel